-
PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation
Tuesday, February 7, 2023 - 4:36pm | 304Read More...Specialty ketamine company PharmaTher Holdings Ltd. (OTCQB: PHRRF) submitted its Type B meeting package to the FDA to discuss the remaining requirements for the KETARX on-body pump system and submit the corresponding New Drug Application (NDA) under the 505(b)(2) pathway by the end of 2023. See...
-
EXCLUSIVE: Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains
Monday, January 23, 2023 - 12:27pm | 816Read More...(This is part two of a four-part series) Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction A compound developed by Israeli psychedelics company Clearmind Medicine (NASDAQ: CMND) would act by providing a similar feeling to...
-
European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed
Tuesday, October 11, 2022 - 5:07pm | 615Read More...UK psychedelics clinical research organization Clerkenwell Health raised $2.047.710 (£2.1 million) in seed funding, bringing the total to date up to $2.437.750 (£2.5 million), all of which will be used to get the London-based startup fully operational. Investors of the seed funding...
-
Sanofi, Regeneron Report Positive Phase 3 Results For Asthma Drug Dupixent's Use In Children
Tuesday, October 13, 2020 - 5:46am | 418Read More...Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) disclosed that their asthma drug Dupixent (dupilumab) met its primary and all key secondary endpoints in randomized Phase 3 clinical trials demonstrating improved lung functions in children aged between six to 11 years. Data...
-
Spectrum Pharmaceuticals Shares Up 5% Following FDA Accelerated Approval For Beleodaq (SPPI)
Thursday, July 3, 2014 - 11:46am | 275Read More...Shares of Spectrum Pharmaceuticals (NASDAQ: SPPI) gained 5.7 percent following the U.S. Food and Drug Administration's approval of the New Drug Application (NDA) for Beleodaq. Accelerated Approval for Beleodaq In an 8-K filing on Wednesday, Spectrum reported that it gained accelerated...
